Quotes 5-day view Delayed Nasdaq
01/12/2021
01/13/2021
01/14/2021
01/15/2021
01/19/2021
Date
1.65(c)
1.63(c)
1.65(c)
1.67(c)
1.78
Last
1 319 182
1 038 283
1 269 878
1 571 494
3 844 624
Volume
+1.85%
-1.21%
+1.23%
+1.21%
+6.59%
Change
Sales 2020
21,9 M
-
-
Net income 2020
-206 M
-
-
Net Debt 2020
-
-
-
P/E ratio 2020
-0,87x
Yield 2020
-
Sales 2021
61,9 M
-
-
Net income 2021
-79,1 M
-
-
Net Debt 2021
-
-
-
P/E ratio 2021
-3,98x
Yield 2021
-
Capitalization
280 M
280 M
-
Capi. / Sales 2020
12,8x
Capi. / Sales 2021
4,53x
Nbr of Employees
40
Free-Float
-
Vyne Therapeutics Inc., formerly Menlo Therapeutics Inc., is a biopharmaceutical company. The Company is focused on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with dermatologic conditions, such as atopic dermatitis, psoriasis and prurigo nodularis. The Company is focused on developing and commercializing a variety of solutions using its Molecule Stabilizing...
Notations Surperformance© of VYNE Therapeutics Inc.
Trading Rating :
Investor Rating :
All news about VYNE THERAPEUTICS INC.
News in other languages on VYNE THERAPEUTICS INC.
- No features available -
Chart VYNE THERAPEUTICS INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends VYNE THERAPEUTICS INC.
Short Term Mid-Term Long Term Trends Bearish Neutral Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
7
Average target price
5,93 $
Last Close Price
1,67 $
Spread / Highest target
499%
Spread / Average Target
255%
Spread / Lowest Target
79,6%
Please enable JavaScript in your browser's settings to use dynamic charts.